In April 2025, the vitamin market overall showed a stable trend with a slight downward bias.
On 1 April, 2025, the marketing application for the vitamin K1 drops for newborns, innovatively developed by Minglei Weisheng, was approved by the National Medical Products Administration.
On 1 April, 2025, Haineng Bioengineering held a high-standard release ceremony for 25-hydroxyvitamin D3 products.
On 2 April 2025, the U.S. announced the imposition of a 34% tariff on goods imported from China, with the main vitamin products included in the U.S. tariff exemption list.
Project Progress of Multiple Companies:
- Garden Biopharma's biotin and VB6 projects
- Guangji Pharmaceutical's 1000 t/a (1%) vitamin B12 comprehensive utilisation project
- Yize Pharmaceutical's 1,000 t/a vitamin B6 project
- Chengyi Pharma's 200KG vitamin K1 active pharmaceutical ingredient project
The USD/RMB exchange rate in this Report is USD1.00=CNY7.1775 on 1 April 2025, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.
Please purchase to view
Add to cart
